NanoVibronix’s (NASDAQ: NAOV) share price is rallying premarket on the news that it intends to enter the Over-the-Counter pain relief market.
The company, which produces the UroShield and PainShield Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, will roll out its PainShield RELIEF, a non-prescription “ultrasound therapy device that delivers fast pain relief for nerve and soft tissue damage.”
NanoVibronix said it has submitted its trademark application to the U.S. Patent and Trademark Office and expects to submit for clearance to the U.S. Food and Drug Administration (FDA) in the very near term.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Brian Murphy, CEO of NanoVibronix, commented: “Entering the OTC pain relief market with our newest product in the PainShield family significantly expands our total addressable market and opens up new opportunities for growth through several additional revenue streams.
“Those suffering from pain will have ready access to the device with no need for clinician prescription. Plans are under way for an official launch in the U.S. and select parts of the world and product reveal in the coming months at a number of trade shows targeting a variety of athletic interests including tennis and golf.
“We are targeting the specific pain relief indications and the retail channels to address them as an OTC alternative to less effective interventions. The company expects widespread availability by early to mid-2022.”
The company’s shares have climbed to $3.17 premarket, up 25.8%.
Should You Invest in NanoVibronix Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now